TaRGETed Therapy with Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy (TaRGET)
About the Study
The TaRGET trial is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 beta (GSK3β) inhibitor, in genotype positive arrhythmogenic cardiomyopathy (ACM). In this trial ‘genotype positive’ refers to a pathogenic or likely pathogenic desmosomal (PKP2, DSG2, DSC2, DSP, or JUP*) rare variant OR the TMEM43-p.S358L variant. Please consult with your inherited arrhythmia specialist if you are unsure of your eligibility for this trial. You can read more here →
Multi-Centre: This term means that the study is being carried out at multiple hospitals or clinics.
Prospective: A prospective trial is one in which participants are followed over time to see how the treatment affects them. This means the study looks forward, from the point of enrollment into the future, to gather data.
Randomized: In a randomized trial, participants are randomly assigned to either the treatment group or the control group. This process helps ensure that the study is fair and that the results are not influenced by any outside factors.
Double-blind: Double-blind means that neither the participants in the study nor the researchers know who is receiving the real treatment and who is receiving the placebo. This helps prevent biases in interpreting the results.
Placebo-controlled: A placebo-controlled trial includes a group of participants who receive a placebo, an inactive substance that looks like the treatment but has no therapeutic effect. Comparing the results of the treatment group to the placebo group helps researchers understand the treatment’s actual effect.
Pathogenic: A change in the DNA sequence of a gene that causes a person to have or be at risk of developing a certain genetic disorder or disease.
To learn more about the study and it’s background information you may click here →
SADS Expert Insights – Evaluation of a Potential Disease Modifying Therapy for Arrhythmogenic Right Ventricular Cardiomyopathy: The TaRGET Trial
You can also learn more about the TaRGET trial by watching our SADS Expert Insights webinar featuring principal investigator of the TaRGET Trial, Dr. Jason Roberts.
If you think you may be eligible to participate in this clinical trial, please contact your cardiologist or the closest participating clinical site. See the list of participating Canadian clinics below or visit https://classic.clinicaltrials.gov/ct2/show/NCT06174220.
Participating Canadian Sites
- Hamilton General Hospital
- Toronto General Hospital
- London Health Sciences Centre
- Ottawa Heart Institute
- Kingston General Hospital
- St. Michael’s Hospital
- Sunnybrook Hospital
- Centenary Hospital
- Southlake Regional Health Centre
- Montreal Heart Institute
- McGill University Health Centre
- Quebec Heart and Lung Institute
- Hospital of the Sacre Coeur
- University of British Columbia
- Queen Elizabeth II Health Sciences Centre
- Health Sciences Centre
- University of Calgary
- University of Manitoba
Senior Scientist, Steering Committee Chair
Stuart Connolly is a Professor of Medicine at McMaster University and a cardiac electrophysiologist at Hamilton Health Sciences.
Scientist, Principal Investigator
Jason Roberts is a clinical cardiac electrophysiologist at Hamilton Health Sciences and an Associate Professor of Medicine at McMaster University.